1.Subtle Pleural Metastasis without Large Effusion in Lung Cancer Patients: Preoperative Detection on CT.
Jung Hwa HWANG ; Koun Sik SONG ; Seung Il PARK ; Tae Hwan LIM ; Kui Hyang KWON ; Dong Erk GOO
Korean Journal of Radiology 2005;6(2):94-101
OBJECTIVE: We wanted to describe the retrospective CT features of subtle pleural metastasis without large effusion that would suggest inoperable lung cancer. MATERIALS AND METHODS: We enrolled 14 patients who had open thoracotomy attempted for lung cancer, but they were proven to be inoperable due to pleural metastasis. Our study also included 20 control patients who were proven as having no pleural metastasis. We retrospectively evaluated the nodularity and thickening of the pleura and the associated pleural effusion on the preoperative chest CT scans. We reviewed the histologic cancer types, the size, shape and location of the lung cancer and the associated mediastinal lymphadenopathy. RESULTS: Subtle pleural nodularity or focal thickening was noted in seven patients (50%) having pleural metastasis and also in three patients (15%) of control group who were without pleural metastasis. More than one of the pleural changes such as subtle pleural nodularity, focal thickening or effusion was identified in eight (57%) patients having pleural metastasis and also in three patients (15%) of the control group, and these findings were significantly less frequent in the control group patients than for the patients with pleural metastasis (p = 0.02). The histologic types of primary lung cancer in patients with pleural metastasis revealed as adenocarcinoma in 10 patients (71%) and squamous cell carcinoma in four patients (29%). The location, size and shape of the primary lung cancer and the associated mediastinal lymphadenopathy showed no significant correlation with pleural metastasis. CONCLUSION: If any subtle pleural nodularity or thickening is found on preoperative chest CT scans of patients with lung cancer, the possibility of pleural metastasis should be considered.
Adenocarcinoma/radiography/secondary
;
Adult
;
Aged
;
Carcinoma, Squamous Cell/radiography/secondary
;
Female
;
Humans
;
Lung Neoplasms/*pathology
;
Male
;
Middle Aged
;
Pleural Effusion, Malignant/pathology
;
Pleural Neoplasms/*radiography/*secondary
;
Preoperative Care
;
Retrospective Studies
;
*Tomography, X-Ray Computed
2.Fluid Retention Associated with Imatinib Treatment in Patients with Gastrointestinal Stromal Tumor: Quantitative Radiologic Assessment and Implications for Management.
Kyung Won KIM ; Atul B SHINAGARE ; Katherine M KRAJEWSKI ; Junhee PYO ; Sree Harsha TIRUMANI ; Jyothi P JAGANNATHAN ; Nikhil H RAMAIYA
Korean Journal of Radiology 2015;16(2):304-313
OBJECTIVE: We aimed to describe radiologic signs and time-course of imatinib-associated fluid retention (FR) in patients with gastrointestinal stromal tumor (GIST), and its implications for management. MATERIALS AND METHODS: In this Institutional Review Board-approved, retrospective study of 403 patients with GIST treated with imatinib, 15 patients with imaging findings of FR were identified by screening radiology reports, followed by manual confirmation. Subcutaneous edema, ascites, pleural effusion, and pericardial effusion were graded on a four-point scale on CT scans; total score was the sum of these four scores. RESULTS: The most common radiologic sign of FR was subcutaneous edema (15/15, 100%), followed by ascites (12/15, 80%), pleural effusion (11/15, 73%), and pericardial effusion (6/15, 40%) at the time of maximum FR. Two distinct types of FR were observed: 1) acute/progressive FR, characterized by acute aggravation of FR and rapid improvement after management, 2) intermittent/steady FR, characterized by occasional or persistent mild FR. Acute/progressive FR always occurred early after drug initiation/dose escalation (median 1.9 month, range 0.3-4.0 months), while intermittent/steady FR occurred at any time. Compared to intermittent/steady FR, acute/progressive FR was severe (median score, 5 vs. 2.5, p = 0.002), and often required drug-cessation/dose-reduction. CONCLUSION: Two distinct types (acute/progressive and intermittent/steady FR) of imatinib-associated FR are observed and each type requires different management.
Adult
;
Aged
;
Aged, 80 and over
;
Antineoplastic Agents/*adverse effects/therapeutic use
;
Ascites/pathology/radiography
;
Benzamides/*adverse effects/therapeutic use
;
Echocardiography/methods
;
Edema/pathology/radiography
;
Female
;
Gastrointestinal Stromal Tumors/drug therapy/pathology/*radiography
;
Gastrointestinal Tract/pathology/*radiography
;
Heart Failure/radiography
;
Humans
;
Male
;
Middle Aged
;
Molecular Targeted Therapy/*adverse effects
;
Pericardial Effusion/pathology/radiography
;
Peritoneal Neoplasms/diagnosis/radiography/secondary
;
Piperazines/*adverse effects/therapeutic use
;
Pleural Effusion/pathology/radiography
;
Pyrimidines/*adverse effects/therapeutic use
;
Radiology
;
Retrospective Studies
;
Tomography, X-Ray Computed